Upadacitinib Demonstrates Superiority vs Adalimumab, Placebo in Treatment-Resistant RA
Upadacitinib resulted in greater improvements in rheumatoid arthritis signs and symptoms compared with placebo and adalimumab.
Upadacitinib resulted in greater improvements in rheumatoid arthritis signs and symptoms compared with placebo and adalimumab.
Real-time patient input about treatment satisfaction can improve management strategies in patients with rheumatoid arthritis.
Patients generally experienced pain relief over 5 years regardless of whether they received physical therapy or arthroscopic partial menisectomy.
The ACR/ARHP 2018 annual meeting will take place from Saturday, October 19, through Wednesday, October 24, in Chicago, Illinois.
Researchers examined the use of dual-energy computed tomography gout imaging in clinical practice from 2007 to 2016.
The ASBMR Secondary Fracture Prevention Initiative Coalition outlined recommendations to improve efforts to increase diagnosis and treatment of individuals who are at high risk for osteoporosis.
The risk for subsequent osteoporotic fracture was elevated for both sexes over a 25-year follow-up period.
Although a combination of lesinurad 200 mg and xanthine oxidase inhibitor therapy was effective and well-tolerated among patients with gout, clinical gout-related benefits were not improved.
TNFi treatment is not associated with increased risk for cancer recurrence in patients with rheumatoid arthritis
Data indicate that drug-naive new onset systemic lupus erythematosus was likely to involve silent cardiac impairment.